Document is current
Any future updates will be listed below
-
Authors
Delaby, Constance
Alcolea, Daniel
Hirtz, Christophe
Vialaret, Jérôme
Kindermans, Jana
Morichon, Lisa
Fortea, Juan
Belbin, Olivia
Gabelle, Audrey
Blennow, Kaj
Zetterberg, Henrik
Lleó, Alberto
Lehmann, Sylvain http://orcid.org/0000-0001-6117-562X
-
Funding
Funding for this research was provided by:
Fondation Claude Pompidou
H2020 Marie Skłodowska-Curie Actions (MIRIADE, MIRIADE)
European Metrology Programme for Innovation and Research (Neuromet2)
Swedish Research Council (#2018-02532)
H2020 European Research Council (681712)
Swedish State Support for Clinical Research (ALFGBG-720931)
Alzheimer's Drug Discovery Foundation (201809-2016862)
Alzheimer's Association (ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C)
Olav Thon Foundation
Richard and Susan Smith Family Foundation
Stiftelsen för Gamla Tjänarinnor (FO2019-0228)
UK Dementia Research Institute
- License Information
-
More Information
Article History
Received: 30 December 2021
Accepted: 5 February 2022
First Online: 15 February 2022
Declarations
:
: Dr. Lleó has served as a consultant or at advisory boards for Fujirebio-Europe, Roche, Biogen, Zambon and Nutricia. In addition, Dr. Lleó has a patent WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease issued. Dr. Alcolea participated in advisory boards from Fujirebio-Europe and Roche Diagnostics and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmacéutica S.L., Zambon S.A.U. and Esteve Pharmaceuticals S.A. In addition, Dr. Alcolea has a patent WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease issued. Dr. Lehmann has served as a consultant or at advisory boards for Fujirebio-Europe, Roche Diagnostics, Shimadzu and Euroimmun. Dr. Zetterberg has served at scientific advisory boards and/or as a consultant for Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, CogRx and Red Abbey Labs, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. All other authors declare that they have no competing interests.
